Sunitinib Versus Interferon Alfa in Renal Cell Cancer Therapy
Cancer is an abnormal multiplication of cells and uncontrolled damage as a result of the structure of DNA that regulate cell multiplication process as a result damage the normal function of cells within an organ. Neither if the cancer cells attack the kidney epithelial cell kidney cancer occurred.
If you see the number of renal cell cancer, many patients who could not survive for long because the early symptoms of renal cell cancer had appeared after the cancer metastasizes (spreads) to other organs. Treatment options such as sunitinib and interferon Alfa is still questionable effectiveness in improving the condition of cancer renal cells. According to The New England Journal of Medicine January 11, 2007 edition, has conducted research to test the effectiveness of sunitinib therapy with interferon Alfa. Research with 750 renal cell cancer patients who had never been treated, were treated in random order during the duration of 6 weeks with sunitinib orally 50 mg / day for 4 weeks and 2 weeks without treatment. While interferon Alfa given for 6 weeks with a dose of 9 MU, 3 times per week by subcutaneous injection.
How did it go? Renal cell cancer patients with sutinitib therapy survived to 11 months with the accuracy of the analysis (95% CI, 10 to 12) while interferon Alfa is only 5 months (95% CI, 4 to 6) and the hazard ratio was 0:42 (95% CI, 0.32 to 0:54; P, 0001). Renal cell cancer did not provide improved response to interferon Alfa therapy, although interferon Alfa has been used for 20 years. Thus, sunitinib can improve the quality of life and can reduce the death rate due to renal cell cancer.







